Poster Proofs evaluated and the implants were harvested at predetermined time points for analysis (n=6 animals per group). Histology and immunohistochemistry were performed to test if PHCS can enhance the therapeutic effects of STSG.
PURPOSE:
Severe burn injury is associated with delayed or failed repair of skin and soft tissue. Following burn injury, impaired tissue healing occurs both at the site of injury and in tissue concurrently injured with, but anatomically remote from, the injury. Thus, the predominate hypothesis is that severe injury provokes derangements in circulating acute phase reactants necessary for soft tissue repair, contributing to pathologic changes in tissue healing. It has been determined that failure to remove fibrin, the major constituent of the coagulation matrix, impairs healing of all tissues. Plasmin is the principle protease responsible for removing fibrin and is essential for the regeneration and healing of all tissues in genetically modified mouse models. It is unknown whether plasmin levels are consumed following significant injuries or whether changes in plasmin levels below a critical threshold contribute to pathologic healing. The purpose of this study is to determine whether plasmin levels are consumed following burn injury in humans and whether plasmin levels are associated with pathologic tissue healing and regeneration in mouse models following a burn injury. We postulate that a significant burn injury influences plasmin levels contributing to poor healing at both the site of burn injury and in tissue anatomically remote from the injury.
METHODS:
All human and animal studies were approved by Vanderbilt IRB and IACUC respectively. Circulating plasminogen levels were determined using a commercial sandwich ELISA (Molecular Innovations; Novi, MI) from human burn patient plasma samples obtained one and three days following burn injury. All murine burn studies were conducted in 6-week-old male mice. After adequate anesthesia, a full thickness cutaneous burn covering 30% of the total body surface area (TBSA) was induced. To simulate the clinical scenario of superimposed burn and muscle injury, WT mice assigned to the injury cohort were injected with CTX in the lower extremity prior to sustaining a burn injury. Dystrophic calcification at the site of muscle injury was evaluated as a marker of pathologic muscle healing.
RESULTS:
In human patients, significant hypoplasminogenemia occurred following burn injury and persisted through 3-days post burn when compared to controls (p<.05). The extent of hypoplasminogenemia in these patients correlated with the TBSA (p= 0.0014; Spearman r= -0.70, Image B). Similar to human patients, mice who sustained a 30% TBSA burn were also hypoplasminogenemic 3-days post injury. Combined burn and CTX-injected WT mice showed significant radiographic evidence of heterotopic ossification compared to burn alone (p<0.05). The incidence and severity of HO in α2AP ASO -treated mice was significantly decreased compared to control ASO -treated combined burn/muscle injury mice (p<0.001).
CONCLUSION:
This data provides evidence that significant burn injury leads to derangements in systemic plasmin levels that result in poor tissue healing both at the site of injury and in an anatomically remote site. Pharmacologic intervention to preserve circulating plasmin levels may drastically improve outcomes in patients sustaining significant injuries. PURPOSE: Split thickness skin graft (STSG) implantation is one of the standard therapies for full thickness wound repair when autologous skin full thickness graft (FTG) or skin flap transplants are inapplicable. However, STSG are more fragile than FTG and can contract significantly during the healing process. Human mesenchymal stem cells (hMSCs) are capable of accelerating the wound healing process. So we use pre-vascularized hMSC sheets (PHCS) to study if they would further improve the repair quality of STSG.
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METHODS:
In vitro cultured control hMSC cell sheets (HCS) were obtained after four weeks culture in complete culture medium (CCM), then endothelial cells (ECs) were cocultured on top of the hMSC sheets for 1 week to get PHCS. Immunofluorescence staining was used to characterize both cell sheets. The progenitor population and multi-lineage differentiation ability of hMSCs inside the cell sheets were tested. The angiogenic growth factor amount present in the cell sheets was also analyzed using an enzyme-linked immunosorbent assay (ELISA). The cell sheets were applied in combination with an autologous STSG in rats with full thickness skin wound. Graft survival and contraction was
